{
    "clinical_study": {
        "@rank": "119272", 
        "arm_group": {
            "arm_group_label": "GS-9973 + idelalisib", 
            "arm_group_type": "Experimental", 
            "description": "The following dose levels will be studied (GS-9973/idelalisib):\n400 mg/100 mg\n600 mg/100 mg\n800 mg/100 mg\n800 mg/150 mg\nAll drug administrations are orally dosed twice daily (BID)"
        }, 
        "brief_summary": {
            "textblock": "This is a study to evaluate the efficacy, safety, tolerability, and pharmacodynamics of\n      GS-9973 and idelalisib. Participants will be enrolled who have one of the following\n      hematological tumor types: chronic lymphocytic leukemia (CLL), follicular lymphoma (FL),\n      mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), or non-FL indolent\n      non-Hodgkin lymphomas (iNHL; including lymphoplasmacytoid lymphoma/Waldenstr\u00f6m\n      macroglobulinemia [LPL/WM], small lymphocytic lymphoma [SLL], or marginal zone lymphoma\n      [MZL])."
        }, 
        "brief_title": "A Phase 2 of GS-9973 in Combination With Idelalisib in Subjects With Relapsed or Refractory Hematologic Malignancies", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Chronic Lymphocytic Leukemia", 
            "Mantle Cell Lymphoma", 
            "Diffuse Large B-cell Lymphoma", 
            "Indolent Non-Hodgkin's Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Lymphoma, B-Cell", 
                "Lymphoma, Large B-Cell, Diffuse", 
                "Lymphoma, Mantle-Cell", 
                "Hematologic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of B-cell iNHL, DLBCL, MCL, or CLL as documented by medical records and\n             with histology based on criteria established by the World Health Organization\n\n          -  For institutions that have Phase 3 protocols studying idelalisib (GS-1101); subjects\n             with malignancies being studied in these protocols must have failed screening and be\n             registered as a screen failure in the respective idelalisib protocol\n\n          -  Prior treatment for lymphoid malignancy\n\n          -  Presence of radiographically measurable lymphadenopathy or extranodal lymphoid\n             malignancy\n\n          -  Discontinuation of all therapy for the treatment of cancer \u2265 3 weeks before the start\n             of study drug\n\n          -  All acute toxic effects of any prior antitumor therapy resolved to Grade \u2264 1 before\n             the start of study drug\n\n          -  Karnofsky performance status of \u2265 60\n\n          -  Life expectancy of at least 3 months\n\n        Exclusion Criteria:\n\n          -  Known histological transformation from iNHL or CLL to an aggressive form of NHL (ie,\n             Richter transformation)\n\n          -  Known active central nervous system or leptomeningeal lymphoma\n\n          -  Presence of known intermediate- or high-grade myelodysplastic syndrome\n\n          -  Current therapy with agents that reduce gastric acidity, including but not limited to\n             antacids, H2 inhibitors, and proton pump inhibitors\n\n          -  Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of\n             start of study drug\n\n          -  Ongoing liver injury\n\n          -  Ongoing or recent hepatic encephalopathy\n\n          -  Ongoing drug-induced pneumonitis\n\n          -  Ongoing inflammatory bowel disease\n\n          -  Ongoing alcohol or drug addiction\n\n          -  Pregnancy or breastfeeding\n\n          -  History of prior allogeneic bone marrow progenitor cell or solid organ\n             transplantation\n\n          -  Ongoing immunosuppressive therapy\n\n          -  Concurrent participation in an investigational drug trial with therapeutic intent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01796470", 
            "org_study_id": "GS-US-339-0103"
        }, 
        "intervention": [
            {
                "arm_group_label": "GS-9973 + idelalisib", 
                "description": "Orally dosed twice daily", 
                "intervention_name": "GS-9973", 
                "intervention_type": "Drug", 
                "other_name": "GS 9973"
            }, 
            {
                "arm_group_label": "GS-9973 + idelalisib", 
                "description": "Orally dosed twice daily", 
                "intervention_name": "Idelalisib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "GS-1101", 
                    "GS 1101", 
                    "Cal-101", 
                    "Cal 101"
                ]
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "GS-US-339-0103", 
            "SYK inhibitor", 
            "PI3K inhibitor", 
            "GS-9973", 
            "GS 9973", 
            "GS-1101", 
            "GS 1101", 
            "Cal-101", 
            "Cal 101", 
            "idelalisib", 
            "leukemia", 
            "lymphoma", 
            "CLL", 
            "MCL", 
            "DLBCL", 
            "iNHL", 
            "FL", 
            "MZL", 
            "LPL", 
            "SLL", 
            "WM", 
            "Waldenstr\u00f6m's macroglobulinemia"
        ], 
        "lastchanged_date": "January 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Greenbrae", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94904"
                    }, 
                    "name": "Marin Cancer Care"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "La Jolla", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92093"
                    }, 
                    "name": "UC San Diego Moores Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Long Beach", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90813"
                    }, 
                    "name": "Pacific Shores Medical Group"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oxnard", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "93030"
                    }, 
                    "name": "Ventura County Hematology Oncology Specialists"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santa Barbara", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "93105"
                    }, 
                    "name": "Cancer Center of Santa Barbara"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20007"
                    }, 
                    "name": "Georgetown University Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boynton Beach", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33435"
                    }, 
                    "name": "Collaborative Research Group LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mount Sterling", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40353"
                    }, 
                    "name": "Montgomery Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10016"
                    }, 
                    "name": "New York University School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "Weill Cornell Medical College"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14642"
                    }, 
                    "name": "University of Rochester, James P. Wilmot Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Middletown", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45042"
                    }, 
                    "name": "Signal Point Clinical Research Center, LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97239"
                    }, 
                    "name": "Oregon Health and Science University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29414"
                    }, 
                    "name": "Charleston Hematology Oncology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29425"
                    }, 
                    "name": "Hollings Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "MD Anderson Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84106"
                    }, 
                    "name": "Utah Cancer Specialists"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tacoma", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98405"
                    }, 
                    "name": "Northwest Medical Specialties"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Combination With Idelalisib in Subjects With Relapsed or Refractory Hematologic Malignancies", 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "Michael Hawkins, M.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Objective response rate (ORR) as assessed by the Independent Review Committee (IRC), defined as the subjects' best overall response during GS-9973/idelalisib therapy and will include complete response (CR) or partial response (PR) (or very good partial response [VGPR] or minor response [MR] for subjects with LPL/WM)", 
            "measure": "Objective response rate", 
            "safety_issue": "No", 
            "time_frame": "up to 48 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01796470"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Safety: laboratory data, adverse events (AEs), and treatment-emergent AEs will be collected. Safety will be assessed by grading of laboratory values and AEs according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.", 
                "measure": "Safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "up to 48 weeks"
            }, 
            {
                "description": "Maximum tolerated dose level (MTD), defined as the highest dose level that was consistently well tolerated without dose limiting toxicity for the majority (ie, > 50%) of the subject's time on treatment as determined by the investigator for each subject", 
                "measure": "Maximum tolerated dose level", 
                "safety_issue": "No", 
                "time_frame": "up to 48 weeks"
            }, 
            {
                "description": "Progression-free survival (PFS), defined as the interval from the first dose of GS-9973/idelalisib to the earlier of the first documentation of definitive disease progression or death from any cause", 
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "up to 48 weeks"
            }, 
            {
                "description": "Duration of response (DOR), defined as the interval from the time first response (CR or PR [or VGPR or MR for subjects with LPL/WM]) is achieved to the earlier of the first documentation of definitive disease progression or death from any cause", 
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "up to 48 weeks"
            }, 
            {
                "description": "Time to response (TTR), defined as the interval from the first dose of GS-9973/idelalisib to the time response (CR or PR [or VGPR or MR for subjects with LPL/WM]) is first achieved", 
                "measure": "Time to response", 
                "safety_issue": "No", 
                "time_frame": "up to 48 weeks"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}